Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: jaybe who wrote (3995)	11/25/2015 9:00:24 AM
From: DewDiligence_on_SI	Respond to of 4474

effective...irrespective of baseline mutation status. Does Pona work in HCV? :-)

To: jaybe who wrote (3995)	2/12/2016 8:20:04 PM
From: jaybe	Read Replies (1) \| Respond to of 4474

New editorial on November Blood article regarding pona resistance... ..."the efficacy of ponatinib in the patients resistant to multiple TKIs could be explained not only by its ability to inactivate BCR-ABL1 mutations, but also by its aptitude to suppress other oncogenic routes than those strictly dependent on the BCR-ABL1 TK activity. Indeed ponatinib is known to be a multikinase inhibitor. This consideration may support a more extensive investigation of the efficacy of ponatinib, either in early chronic-phase CML, because of its ability to suppress mutations and controvert genomic instability, as well as in Ph-negative hematologic malignancies, owing to its multitarget activity." bloodjournal.org